XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2017
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based compensation expense   $ 50,418 $ 26,684 $ 182,508 $ 84,161
Grants, Stock options   127,100 91,200 1,626,220 1,522,947
Chief Executive Officer          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Grants, Stock options 3,300,000        
Minimum [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Compound annual growth rate       5.00%  
Unvested Tranche Member          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Stock-based compensation expense   $ 20,500   $ 94,200  
Incremental compensation cost       $ 29,400  
Vesting, Stock options   550,110   550,110  
Average closing price   $ 105.74   $ 105.74  
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award       550,110 options relating to the Unvested Tranche met the conditions for vesting in that the average closing price of the Company's common stock exceeded $105.74 during 20 consecutive trading days in August 2022 and the compound annual growth rate of the Company's common stock exceeded that of the Nasdaq Biotech Index by greater than 5%